未登录.png)
分享.png)
收藏分享 收藏 Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)GEMSTONE-302研究四年随访结果：转移性非小细胞肺癌（NSCLC）一线治疗中使用苏格莫利单抗联合铂类为基础的化疗
Zhou, C.; Wang, Z.; Sun, M.; Cao, L.; Ma, Z.; Wu, R.; Yu, Y.; Yao, W.; Sun, S.; Chen, J.; Zhuang, W.; Cui, J.; Chen, X.; Lu, Y.; Hu, C.; Wang, J.; Wang, Q.; Wang, B.; Dai, H.; Yang, J. J. 分享 收藏 分享 收藏 分享 收藏 RATIONALE-307: Safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLCYu, X.; Wang, J.; Hu, Y.; Sun, Y.; Zhao, J.; Yu, Y.; Hu, C.; Yang, K.; Feng, G.; Leaw, S. J.; Yuan, Y.; Lin, X.; Bai, F.; Lu, S. 分享 收藏 分享 收藏 分享 收藏 RATIONALE 307: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokersYu, X.; Wang, J.; Lu, S.; Zhao, J.; Yu, Y.; Hu, C.; Feng, G.; Ying, K.; Zhuang, W.; Zhou, J.; Wu, J.; Leaw, S. J.; Lin, X.; Zhang, J. 分享 收藏 Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)Wang, J.; Lu, S.; Hu, C.; Sun, Y.; Yang, K.; Chen, M.; Zhao, J.; Yu, G.; Zhou, X.; Feng, G.; Pan, Y.; Yu, Y.; Zhang, J.; Liang, L.; Lin, X.; Wu, X.; Cui, J. 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
